5-MeO-DALT - PsychonautWiki

5-MeO-DALT

Summary sheet: 5-MeO-DALT
5-MeO-DALT
5-MeO-DALT.svg
Chemical Nomenclature
Common names 5-MeO-DALT, Foxtrot
Substitutive name N,N-Diallyl-5-methoxytryptamine
Systematic name N-Allyl-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]prop-2-en-1-amine
Class Membership
Psychoactive class Psychedelic
Chemical class Tryptamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.


⇣ Smoked
Dosage
Threshold 3 mg
Common 5 - 10 mg
Duration
Total 15 - 20 minutes
Onset 15 - 60 seconds
Peak 1 - 5 minutes
Offset 5 - 10 minutes
After effects 5 - 10 minutes
⇣ Oral
Dosage
Threshold 4 mg
Light 5 - 12 mg
Common 12 - 25 mg
Strong 25 - 35 mg
Heavy 35 mg +
Duration
Total 3 - 6 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
2C-T-X
2C-X
Cannabis
DOx
MDMA
Mescaline
NBOMe
Amphetamines
Cocaine
DXM
Tramadol
aMT
MAOIs
PCP


N,N-Diallyl-5-methoxytryptamine (also known as 5-MeO-DALT or colloquially as Foxtrot) is a lesser-known psychedelic substance of the tryptamine class that produces short-lived psychedelic effects when administered. It is structurally related to tryptamines like 5-MeO-DiPT and DALT, although it is reported to produce distinct effects.

5-MeO-DALT was first synthesized by Alexander Shulgin, who sent the first material regarding the synthesis and effects to a researcher in May 2004. This material was subsequently circulated online and the compound soon appeared on the online research chemical market. In August 2004, the synthesis and effects of 5-MeO-DALT were officially published by Erowid.[1] Reports linked to the detection of 5-MeO-DALT began to surface in 2007.[2]

Anecdotal reports characterize the effects of this substance as being primarily physical in nature, lacking the characteristic visual distortions or perceptual depth of most psychedelics. Its headspace has been described as "shallow," albeit suited for sexual contexts due to its potent stimulating and libidinous effects. It is also reported to produce more uncomfortable cardiovascular effects such as increased blood pressure and heart rate relative to other psychedelics. This has raised questions about possible toxicity associated with long-term or heavy uses.

Very limited data exists about the pharmacological properties, metabolism, and toxicity of 5-MeO-DALT, and it has a very short history of human use. It is highly advised to use harm reduction practices if using this substance.

Chemistry

 

This chemistry section is incomplete.

You can help by adding to it.

The full name of the chemical is N-allyl-N-[2-(5-methoxy-1H-indol-3-yl)ethyl] prop-2-en-1- amine. It is related to the compounds 5-MeO-DPT and DALT (N,N-Diallyltryptamine).

5-MeO-DALT is named for its chemical structure 5-MethOxy-DiALlylTryptamine. It contains two allyl groups bound to the amino group and a 5-methoxy group bound to the indole ring of tryptamine. It is a structural analog of DALT and 5-MeO-DiPT. 5-MeO-DALT is an off-white powder at room temperature.

Pharmacology

Further information: Serotonergic psychedelic

5-MeO-DALT binds to 5-HT1A, 5-HT1D, 5-HT1E, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6, α2A, α2B, α2C, H1, κ-opioid, σ1 and σ2 receptors with Ki values lower than 10μM and also acts as a DAT and SERT monoamine reuptake inhibitor.[3]

5-MeO-DALT acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from its efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience remains the subject of ongoing scientific investigation.

5-MeO-DALT has been used as an intermediate in the preparation of radiolabeled diethyltryptamine.[4]

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects
 

Visual effects
 

  • Enhancements

    Distortions

    Geometry

    The visual geometry that is present throughout the experience can be described as more similar in appearance to that of AMT than that of LSD, 2C-B or 2C-I. It can be comprehensively described as unstructured in its organization, synthetic in geometric style, intricate in complexity, small in size, slow and smooth in motion, colourful in scheme, glossy in colour, equally blurred and sharp in its edges and equally rounded and angular in its corners. It possesses a synthetic feel that is less impressive than most of the "classical" psychedelics at any level. It has yet to be confirmed whether this compound results in either level 8A or level 8B geometry at heavy doses.

Cognitive effects
 

Auditory effects
 

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential

 

This toxicity and harm potential section is a stub.

As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Note: Always conduct independent research and use harm reduction practices if using this substance.

Further information: Research chemicals § Toxicity and harm potential, and Responsible use § Hallucinogens

The toxicity and long-term health effects of recreational 5-MeO-DALT use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 5-MeO-DALT is a research chemical with very little history of human usage.

Anecdotal reports from those who have tried 5-MeO-DALT suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

5-MeO-DALT is not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of 5-MeO-DALT is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 5-MeO-DALT presents cross-tolerance with all psychedelics, meaning that after the consumption of 5-MeO-DALT all psychedelics will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

  • 2C-T-X - Both classes of compounds can be unpredictable alone.
  • 2C-X - The 5-MeO psychedelics can interact unpredictably to potentiate other psychedelics.
  • Cannabis - May increase the risk of negative psychological effects such as anxiety, paranoia, and psychosis.
  • DOx - The 5-MeO class of tryptamines can be unpredictable in their interactions, particularly increasing the risk of unpleasant physical side effects.
  • MDMA - Some of the 5-MeO tryptamines are a bit unpredictable and should be mixed with MDMA with care.
  • Mescaline - The 5-MeO class of tryptamines can be unpredictable in their interactions.
  • NBOMe - The 5-MeO class of tryptamines can be unpredictable in their interactions and the NBOMes are known to be unpredictable even alone. This combination is best avoided.
  • Amphetamines - The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally unnecessary because of the stimulating effects of psychedelics.
  • Cocaine - The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally unnecessary because of the stimulating effects of psychedelics.
  • DXM - Little information exists about this combination.
  • Tramadol - Increased risk of serotonin syndrome.
  • aMT - Increased risk of serotonin syndrome.
  • MAOIs - Increased risk of serotonin syndrome.
  • PCP - Little information exists about this combination. May increase risk of psychosis and excessive stimulation.

Legal status

  • Austria: Since January 1, 2012, 5-MeO-DALT is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).[citation needed]
  • China: 5-MeO-DALT is a controlled substance in China as of October 2015.[5]
  • Germany: 5-MeO-DALT is controlled under the NpSG[6] (New Psychoactive Substances Act) as of July 18, 2019.[7] Production and import with the aim to place it on the market, administration to another person, placing it on the market and trading is punishable. Possession is illegal but not punishable.[8][9] The legislator considers it possible that orders of 5-MeO-DALT are punishable as an incitement to place it on the market.[10]
  • Japan: 5-MeO-DALT became a controlled substance in Japan in April 2007 due to an amendment to the Pharmaceutical Affairs Law.[11]
  • Sweden: 5-MeO-DALT is a Schedule I substance in Sweden as of May 1, 2012. It was published by Medical Products Agency in their regulation LVFS 2012:6.[12]
  • Slovakia : 5-MeO-DALT is a Schedule I substance in Slovakia as of December 1, 2021
  • Switzerland: 5-MeO-DALT is a controlled substance specifically named under Verzeichnis E.[13]
  • United Kingdom: 5-MeO-DALT is a Class A drug in the UK as it is an ether of the drug 5-HO-DALT, which is a Class A drug as a result of the tryptamine catch-all clause.[14]
  • United States: 5-MeO-DALT is unscheduled in the United States. It may be considered an analogue of 5-MeO-DiPT, a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.[citation needed]
    • Florida: 5-MeO-DALT is a Schedule I controlled substance in the state of Florida, making it illegal to buy, sell, or possess.[15]

See also

External links

Discussion

Literature

  • Brandt, S. D., Kavanagh, P. V., Dowling, G., Talbot, B., Westphal, F., Meyer, M. R., ... & Halberstadt, A. L. (2017). Analytical characterization of N, N‐diallyltryptamine (DALT) and 16 ring‐substituted derivatives. Drug Testing and Analysis, 9(1), 115-126. https://doi.org/10.1002/dta.1974

References

  1. ↑ Hamilton Morris; Ash Smith (May 2, 2010). "The Last Interview With Alexander Shulgin". vice.com. Retrieved August 28, 2020. 
  2. ↑ Brandt, S. D.; Kavanagh, P. V.; Dowling, G.; Talbot, B.; Westphal, F.; Meyer, M. R.; Maurer, H. H.; Halberstadt, A. L. (2017). "Analytical characterization of N, N‐diallyltryptamine (DALT) and 16 ring‐substituted derivatives". Drug Testing and Analysis. 9 (1): 115–126. doi:10.1002/dta.1974. eISSN 1942-7611. ISSN 1942-7603. OCLC 231680670. PMC 5412731  . PMID 27100373. 
  3. ↑ Cozzi, N. V., Daley, P. F. (February 2016). "Receptor binding profiles and quantitative structure–affinity relationships of some 5-substituted- N , N -diallyltryptamines". Bioorganic & Medicinal Chemistry Letters. 26 (3): 959–964. doi:10.1016/j.bmcl.2015.12.053. ISSN 0960-894X. 
  4. ↑ Brandt, S. D., Tirunarayanapuram, S. S., Freeman, S., Dempster, N., Barker, S. A., Daley, P. F., Cozzi, N. V., Martins, C. P. B. (November 2008). "Microwave-accelerated synthesis of psychoactive deuterated N , N -dialkylated-[ α , α , β , β -d 4 ]-tryptamines". Journal of Labelled Compounds and Radiopharmaceuticals. 51 (14): 423–429. doi:10.1002/jlcr.1557. ISSN 0362-4803. 
  5. ↑ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). 国家食品药品监督管理总局 [China Food and Drug Administration]. September 27, 2015. Retrieved 1 October 2015. 
  6. ↑ "Anlage NpSG" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  7. ↑ "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag (published July 17, 2019). July 12, 2019. pp. 1083–1094. ISSN 0341-1095. 
  8. ↑ "§ 4 NpSG" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  9. ↑ "§ 3 NpSG" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  10. ↑ "Gesetzentwurf der Bundesregierung: Entwurf eines Gesetzes zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe" (PDF) (in German). Deutscher Bundestag. May 30, 2016. p. 20. Drucksache 18/8579. 
  11. ↑ "厚生労働省：平成１8年度無承認無許可医薬品等買上調査の結果について" (in Japanese). 厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)]. August 10, 2007. Retrieved June 26, 2012. 
  12. ↑ "Föreskrifter om ändring i Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika" (PDF) (in Swedish). Läkemedelsverket [Medical Products Agency ] (published April 30, 2012). April 20, 2012. ISSN 1101-5225. LVFS 2012:6. Archived from the original (PDF) on October 31, 2018. 
  13. ↑ "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  14. ↑ "Schedule 2: Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved August 20, 2020. 
  15. ↑ "Chapter 893: Drug Abuse Prevention and Control". The 2019 Florida Statutes. The Florida Legislature. Retrieved August 21, 2020. 


Retrieved from ‘https://psychonautwiki.org/w/index.php?title=5-MeO-DALT&oldid=160504’